Tag: Abraxane

In a clinical study for metastatic breast cancer, Abraxane demonstrated a higher overall response rate compared to solvent-based paclitaxel. But what kind of chemo is Abraxane? It's a type of taxane chemotherapy that utilizes an innovative delivery system.

While groundbreaking advancements have been made in cancer therapy, many patients and caregivers are left to wonder about the mechanisms of their treatments. Abraxane is a drug that has been pivotal in extending the lives of some cancer patients, but its classification can be confusing: Is Abraxane chemo or immunotherapy? This is an essential distinction for understanding how it combats cancer and how it can be combined with newer treatments.

Abraxane, a unique albumin-bound paclitaxel formulation, received its first U.S. Food and Drug Administration (FDA) approval on January 7, 2005, for the treatment of metastatic breast cancer. This initial approval answered the pivotal question, "When did Abraxane come out?", paving the way for its use in other cancer treatments in the years that followed.